Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world registry of neoadjuvant durvalumab plus chemotherapy followed by surgery and adjuvant durvalumab in resectable NSCLC
jRCT1030260428Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Real-world event-free survival (rwEFS) rate at 36 months. Started Oct 2026; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1030260428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030260428.